Siyuan Tao

Siyuan Tao

Auto-generated profile, based on publicly available information

Siyuan Tao

Laboratory for Biointerfaces Empa Swiss Federal Laboratories for Materials Science and Technology St. Gallen 9014 Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2024 in Advanced Healthcare Materials
Verified
Journal Article
Open access
STSiyuan Tao
Siyuan Tao
SZSixuan Zhang
Sixuan Zhang
KWKongchang Wei
Kongchang Wei
KMKatharina Maniura‐Weber
Katharina Maniura‐Weber
ZLZhihao Li
Zhihao Li
QRQun Ren
Qun Ren
Wound infections pose a significant challenge in healthcare, and traditional antibiotic treatments often result in the development of resistant pathogens. Addressing this gap, ProGel is introduced, a living hydrogel created by entrapping probiotic Lactobacillus plantarum as a therapeutic component within a gelatin matrix. With a double‐syringe system, ProGel can be easily mixed and applied, conforming swiftly to any wound shape and forming hydrogel in situ. It also demonstrates robust mechanical and self‐healing properties owing to the Schiff‐base bonds. ProGel sustains more than 80% viability of the entrapped L. plantarum while restricting their escape from the hydrogel. After a week of storage, more than 70% viability of the entrapped L. plantarum is preserved. Importantly, ProGel exhibits broad‐spectrum antimicrobial efficacy against pathogens commonly associated with wound infections, i.e., Pseudomonas aeruginosa (7Log reduction), Staphylococcus aureus (3‐7Log reduction), and Candida albicans (40–70% reduction). Moreover, its cytocompatibility is affirmed through coculture with human dermal fibroblasts. The effectiveness of ProGel is further highlighted in more clinically relevant tests on human skin wound models infected with P. aeruginosa and S. aureus , where it successfully prevents the biofilm formation of these pathogens. This study showcases an injectable living hydrogel system for the management of complex wound infections.

17 July 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
STSiyuan Tao
Siyuan Tao
AHAnna Hu
Anna Hu
EBElnaz Bavel
Elnaz Bavel
CYChien‐Hsun Yu
Chien‐Hsun Yu
SZSixuan Zhang
Sixuan Zhang
QRQun Ren
Qun Ren
Antimicrobial resistance (AMR) is a critical global health issue, driving the need for novel therapeutic strategies such as bacteriophage (phage) therapy, which offers a comparatively targeted approach to bacterial infections. However, phage therapy faces substantial hurdles, including phage resistance, delivery challenges, insufficient residence time, and reduced antibacterial efficacy with time. This study presents the development of a gelatin‐based hydrogel system designed to deliver a phage cocktail targeting antibiotic‐resistant Pseudomonas aeruginosa and its biofilms. The hydrogel is responsive to P. aeruginosa secreted enzymes, specifically gelatinases, which trigger its degradation and enable the “on‐demand” release of phages for targeted antibacterial action and a prolonged effect. The simultaneous administration of a phage cocktail, FJK.R9‐30 and MK.R3‐15, within this hydrogel effectively addresses the phage resistance challenge. The phage‐hydrogel not only completely inhibits biofilm formation but also disrupts established biofilms. Validation in an ex vivo human skin infection model confirms the hydrogel's specificity in responding to P. aeruginosa and its strong antibiofilm properties. Additionally, the system demonstrates cytocompatibility, showing no cytotoxic effects on human dermal fibroblasts. This multi‐phage hydrogel approach effectively tackles phage resistance and enhances phage localization at infection sites, offering a promising solution for advancing phage therapy in combating the AMR crisis.

18 January 2023 in Macromolecular Bioscience
Verified
Journal Article
Open access
NGNicolas Ghéczy
Nicolas Ghéczy
STSiyuan Tao
Siyuan Tao
SPSajad Pour‐Esmaeil
Sajad Pour‐Esmaeil
KSKatarzyna Szymańska
Katarzyna Szymańska
AJAndrzej B. Jarzębski
Andrzej B. Jarzębski
PWPeter Walde
Peter Walde
Horseradish peroxidase (HRP) is covalently bound in aqueous solution to polycationic α‐poly(D‐lysine) chains of ≈1000 repeating units length, PDL, via a bis‐aryl hydrazone bond (BAH). Under the experimental conditions used, about 15 HRP molecules are bound along the PDL chain. The purified PDL‐BAH‐HRP conjugate is very stable when stored at micromolar HRP concentration in a pH 7.2 phosphate buffer solution at 4 °C. When a defined volume of such a conjugate solution of desired HRP concentration (i.e., HRP activity) is added to a macro‐ and mesoporous silica monolith with pore sizes of 20–30 µm as well as below 30 nm, quantitative and stable noncovalent conjugate immobilization is achieved. The HRP‐containing monolith can be used as flow‐through enzyme reactor for bioanalytical applications at neutral or slightly alkaline pH, as demonstrated for the determination of hydrogen peroxide in diluted honey. The conjugate can be detached from the monolith by simple enzyme reactor washing with an aqueous solution of pH 5.0, enabling reloading with fresh conjugate solution at pH 7.2. Compared to previously investigated polycationic dendronized polymer‐enzyme conjugates with approximately the same average polymer chain length, the PDL‐BAH‐HRP conjugate appears to be equally suitable for HRP immobilization on silica surfaces.

28 November 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
STSiyuan Tao
Siyuan Tao
DDDarine D'ADam
Darine D'ADam
AHAnna Hu
Anna Hu
SZSixuan Zhang
Sixuan Zhang
JRJosua Roduner
Josua Roduner
QRQun Ren
Qun Ren
Wound infections caused by multidrug‐resistant pathogens such as Pseudomonas aeruginosa remain a major clinical challenge due to biofilm formation and the limited efficacy of conventional antibiotics. Living therapeutics, including bacteriophages and probiotics, provide alternative antibacterial effects but face individual limitations. This study investigates the antibacterial synergy of phages and probiotics and develops ProΦGel, a pathogen‐responsive dual‐layer hydrogel designed to coordinate their sequential activity. The inner layer contains Lactobacillus plantarum encapsulated in alginate microbeads generated by aerodynamically assisted jetting, whereas the outer gelatin‐PEG hydrogel incorporates phages through mild Schiff‐base crosslinking. This gentle fabrication process preserves the viability of both agents. Taking advantage of gelatin's pathogen‐degradable nature, phages are released on‐demand at infection sites to provide rapid antibacterial action, followed by delayed probiotic release from microbeads to modulate the wound microenvironment and suppress phage‐resistant variants. This sequential delivery achieves significant eradication of P. aeruginosa and biofilm disruption in vitro and in an ex vivo human skin model. Beyond infection control, the probiotic component enhances fibroblast migration, underscoring the system's intrinsic pro‐healing potential. Thus, the ProΦGel represents a rational material strategy for coordinating multi‐component living therapeutics through responsive and sequential release for advanced wound‐infection therapy.